Duchenne Muscular Dystrophy

Patient in Sarepta gene therapy trial develops serious illness; shares plunge
Patient in Sarepta gene therapy trial develops serious illness; shares plunge
Yahoo/Reuters
Sarepta Therapeutics
Duchenne Muscular Dystrophy
rhabdomyolysis
gene therapy
Flag link:
Studies Show Sarepta's Exondys 51 Slows Respiratory Decline in Muscular Dystrophy Patients
Studies Show Sarepta's Exondys 51 Slows Respiratory Decline in Muscular Dystrophy Patients
BioSpace
Sarepta Therapeutics
Exondys 51
DMD
Duchenne Muscular Dystrophy
Flag link:
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
Yahoo/Zacks.com
Pfizer
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
PF-06939926
Flag link:
Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?
Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?
Motley Fool
gene editing
gene therapy
DMD
Duchenne Muscular Dystrophy
Vertex Pharmaceuticals
CRISPR Therapeutics
Exonics
Flag link:
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
Endpoints
Duchenne Muscular Dystrophy
ICER
Sarepta Therapeutics
Exondys 51
Flag link:
Solid Biosciences’ Duchenne Muscular Dystrophy Drug Has Side Effect Issues
Solid Biosciences’ Duchenne Muscular Dystrophy Drug Has Side Effect Issues
BioSpace
Solid Biosciences
Duchenne Muscular Dystrophy
Flag link:
Wave down on Phase I safety data for DMD therapy
Wave down on Phase I safety data for DMD therapy
BioCentury
Wave Life Sciences
Duchenne Muscular Dystrophy
clinical trials
suvodirsen
Flag link:
Sarepta to seek speedy approval of third DMD drug
Sarepta to seek speedy approval of third DMD drug
Biopharma Dive
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
casimersen
Flag link:
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
Flag link:
CRISPR corrects DMD in mice for a year in Sarepta-supported study
CRISPR corrects DMD in mice for a year in Sarepta-supported study
Fierce Biotech
Duke University
Sarepta Therapeutics
CRISPR
gene editing
DMD
Duchenne Muscular Dystrophy
Flag link:
Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD
Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD
Endpoints
Solid Biosciences
clinical trials
Duchenne Muscular Dystrophy
SGT-001
Flag link:
Suvodirsen For Duchenne Muscular Dystrophy Selected for FDA Complex Innovative Trial Designs Pilot Program
Suvodirsen For Duchenne Muscular Dystrophy Selected for FDA Complex Innovative Trial Designs Pilot Program
CP Wire
suvodirsen
Wave Life Sciences
Duchenne Muscular Dystrophy
muscular dystrophy
Flag link:
Suvodirsen For Duchenne Muscular Dystrophy Selected for FDA Complex Innovative Trial Designs Pilot Program
suvodirsen
Wave Life Sciences
Duchenne Muscular Dystrophy
muscular dystrophy
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
Increase collaboration to widen access to DMD drugs, trials and care
Increase collaboration to widen access to DMD drugs, trials and care
Pharmaforum
Duchenne Muscular Dystrophy
clinical trials
Flag link:
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Forbes
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
Flag link:
Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
CP Wire
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Flag link:
Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Flag link:
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
Endpoints
Sarepta Therapeutics
FDA
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Flag link:
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:

Pages